233 related articles for article (PubMed ID: 24423086)
1. Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.
Altomonte M; Di Giacomo A; Queirolo P; Ascierto P; Spagnolo F; Bajetta E; Calabrò L; Danielli R; de Rosa F; Maur M; Chiarion-Sileni V; Ferrucci P; Giannarelli D; Testori A; Ridolfi R; Maio M
J Exp Clin Cancer Res; 2013 Oct; 32(1):82. PubMed ID: 24423086
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme.
Chiarion Sileni V; Pigozzo J; Ascierto PA; Grimaldi AM; Maio M; Di Guardo L; Marchetti P; de Rosa F; Nuzzo C; Testori A; Cocorocchio E; Bernengo MG; Guida M; Marconcini R; Merelli B; Parmiani G; Rinaldi G; Aglietta M; Grosso M; Queirolo P
J Exp Clin Cancer Res; 2014 Apr; 33(1):30. PubMed ID: 24708900
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.
Del Vecchio M; Di Guardo L; Ascierto PA; Grimaldi AM; Sileni VC; Pigozzo J; Ferraresi V; Nuzzo C; Rinaldi G; Testori A; Ferrucci PF; Marchetti P; De Galitiis F; Queirolo P; Tornari E; Marconcini R; Calabrò L; Maio M
Eur J Cancer; 2014 Jan; 50(1):121-7. PubMed ID: 24100024
[TBL] [Abstract][Full Text] [Related]
4. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).
Di Giacomo AM; Danielli R; Calabrò L; Bertocci E; Nannicini C; Giannarelli D; Balestrazzi A; Vigni F; Riversi V; Miracco C; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2011 Apr; 60(4):467-77. PubMed ID: 21170646
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.
Ascierto PA; Simeone E; Sileni VC; Pigozzo J; Maio M; Altomonte M; Del Vecchio M; Di Guardo L; Marchetti P; Ridolfi R; Cognetti F; Testori A; Bernengo MG; Guida M; Marconcini R; Mandalà M; Cimminiello C; Rinaldi G; Aglietta M; Queirolo P
J Transl Med; 2014 May; 12():116. PubMed ID: 24885479
[TBL] [Abstract][Full Text] [Related]
6. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
Sznol M; Ferrucci PF; Hogg D; Atkins MB; Wolter P; Guidoboni M; Lebbé C; Kirkwood JM; Schachter J; Daniels GA; Hassel J; Cebon J; Gerritsen W; Atkinson V; Thomas L; McCaffrey J; Power D; Walker D; Bhore R; Jiang J; Hodi FS; Wolchok JD
J Clin Oncol; 2017 Dec; 35(34):3815-3822. PubMed ID: 28915085
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases.
Queirolo P; Spagnolo F; Ascierto PA; Simeone E; Marchetti P; Scoppola A; Del Vecchio M; Di Guardo L; Maio M; Di Giacomo AM; Antonuzzo A; Cognetti F; Ferraresi V; Ridolfi L; Guidoboni M; Guida M; Pigozzo J; Chiarion Sileni V
J Neurooncol; 2014 May; 118(1):109-16. PubMed ID: 24532241
[TBL] [Abstract][Full Text] [Related]
8. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.
Danielli R; Ridolfi R; Chiarion-Sileni V; Queirolo P; Testori A; Plummer R; Boitano M; Calabrò L; Rossi CD; Giacomo AM; Ferrucci PF; Ridolfi L; Altomonte M; Miracco C; Balestrazzi A; Maio M
Cancer Immunol Immunother; 2012 Jan; 61(1):41-8. PubMed ID: 21833591
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.
Berrocal A; Arance A; Lopez Martin JA; Soriano V; Muñoz E; Alonso L; Espinosa E; Lopez Criado P; Valdivia J; Martin Algarra S;
Melanoma Res; 2014 Dec; 24(6):577-83. PubMed ID: 25046550
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.
Schadendorf D; Wolchok JD; Hodi FS; Chiarion-Sileni V; Gonzalez R; Rutkowski P; Grob JJ; Cowey CL; Lao CD; Chesney J; Robert C; Grossmann K; McDermott D; Walker D; Bhore R; Larkin J; Postow MA
J Clin Oncol; 2017 Dec; 35(34):3807-3814. PubMed ID: 28841387
[TBL] [Abstract][Full Text] [Related]
11. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.
Ku GY; Yuan J; Page DB; Schroeder SE; Panageas KS; Carvajal RD; Chapman PB; Schwartz GK; Allison JP; Wolchok JD
Cancer; 2010 Apr; 116(7):1767-75. PubMed ID: 20143434
[TBL] [Abstract][Full Text] [Related]
12. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma.
Simeone E; Gentilcore G; Giannarelli D; Grimaldi AM; Caracò C; Curvietto M; Esposito A; Paone M; Palla M; Cavalcanti E; Sandomenico F; Petrillo A; Botti G; Fulciniti F; Palmieri G; Queirolo P; Marchetti P; Ferraresi V; Rinaldi G; Pistillo MP; Ciliberto G; Mozzillo N; Ascierto PA
Cancer Immunol Immunother; 2014 Jul; 63(7):675-83. PubMed ID: 24695951
[TBL] [Abstract][Full Text] [Related]
13. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA
Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997
[TBL] [Abstract][Full Text] [Related]
14. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
Hamid O; Schmidt H; Nissan A; Ridolfi L; Aamdal S; Hansson J; Guida M; Hyams DM; Gómez H; Bastholt L; Chasalow SD; Berman D
J Transl Med; 2011 Nov; 9():204. PubMed ID: 22123319
[TBL] [Abstract][Full Text] [Related]
15. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy.
Chiarion-Sileni V; Pigozzo J; Ascierto PA; Simeone E; Maio M; Calabrò L; Marchetti P; De Galitiis F; Testori A; Ferrucci PF; Queirolo P; Spagnolo F; Quaglino P; Carnevale Schianca F; Mandalà M; Di Guardo L; Del Vecchio M
Br J Cancer; 2014 Apr; 110(7):1721-6. PubMed ID: 24619072
[TBL] [Abstract][Full Text] [Related]
17. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Weber JS; Gibney G; Sullivan RJ; Sosman JA; Slingluff CL; Lawrence DP; Logan TF; Schuchter LM; Nair S; Fecher L; Buchbinder EI; Berghorn E; Ruisi M; Kong G; Jiang J; Horak C; Hodi FS
Lancet Oncol; 2016 Jul; 17(7):943-955. PubMed ID: 27269740
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma.
Maio M; Danielli R; Chiarion-Sileni V; Pigozzo J; Parmiani G; Ridolfi R; De Rosa F; Del Vecchio M; Di Guardo L; Queirolo P; Picasso V; Marchetti P; De Galitiis F; Mandalà M; Guida M; Simeone E; Ascierto PA
Ann Oncol; 2013 Nov; 24(11):2911-5. PubMed ID: 24067719
[TBL] [Abstract][Full Text] [Related]
19. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
Wolchok JD; Neyns B; Linette G; Negrier S; Lutzky J; Thomas L; Waterfield W; Schadendorf D; Smylie M; Guthrie T; Grob JJ; Chesney J; Chin K; Chen K; Hoos A; O'Day SJ; Lebbé C
Lancet Oncol; 2010 Feb; 11(2):155-64. PubMed ID: 20004617
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Ascierto PA; Del Vecchio M; Mandalá M; Gogas H; Arance AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Márquez-Rodas I; Butler MO; Maio M; Middleton MR; de la Cruz-Merino L; Arenberger P; Atkinson V; Hill A; Fecher LA; Millward M; Khushalani NI; Queirolo P; Lobo M; de Pril V; Loffredo J; Larkin J; Weber J
Lancet Oncol; 2020 Nov; 21(11):1465-1477. PubMed ID: 32961119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
